By Daniella Parra Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, said its net loss was $5.4 million for the three months ended March 31, compared to $6.2 million in 2023. The company said an experimental drug to improve...

  By Daniella Parra Creyon Bio, Inc. and Cajal Neuroscience have teamed up to develop therapies for neurodegenerative diseases, they said. The companies aim to accelerate the development of treatments for common neurodegenerative disorders, engineering medicines using human data and...

By Karen Roman Agendia, Inc.’s BluePrint was recently included in the latest version of German Gynecological Oncology Group (AGO) guidelines for chemotherapy decision making. AGO is comprised of gynecological oncologists specialized in breast cancer and interdisciplinary members focused on pathology,...

By Daniella Parra Gameto, a female-led biotechnology firm, said it received tentative FDA approval to move to Phase 3 trials for Fertilo, a pivotal step towards Biologic License Application approval, the company said. The primary efficacy endpoint will assess pregnancy...

By Karen Roman Orthobond Corp. said the Food and Drug Administration approved its request to market Ostaguard, an antibacterial surface treatment used on permanent spine implants. This is the first time the FDA granted approval for a medical device with...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company, announced it signed an agreement with global pharmaceutical and biotech partner Lonza. The collaboration includes the manufacturing of sabirnetug (ACU193), an antibody for the treatment of Alzheimer’s disease...

By Daniella Parra Gameto, a biotech firm focused on women’s healthcare, shared a study examining the impact of minimal controlled ovarian stimulation on egg retrieval experiences. The analysis involved 110 patients with minimal stimulation cycles followed by OSC-IVM, 48 patients...

By Karen Roman REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients. Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its...

By Karen Roman Agendia, Inc., a biotechnology company that provides molecular diagnostics and cancer treatment, said it can predict response and nonresponse to common neoadjuvant immunotherapy for patients with triple negative breast cancer. Agendia holds an FDA Investigational Device Exempt...

By Daniella Parra Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the appointment of Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a Consultant on intellectual property strategies. The company said Dr. Holland brings over 20 years of...